Gastroparesis is a chronic disorder that affects a significant subset of the population. Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

It is driven by rising diabetes rates. The global gastroparesis drugs market is set to grow by $1.42b from 2024 to 2028, with ...

The real-world retrospective study evaluated the impact of GIMOTI (metoclopramide nasal spray) in patients with diabetic gastroparesis (DGP) who were concurrently using GLP-1 receptor agonists.

Ozempic Linked to Gastroparesis It’s crucial to note that Ozempic and Mounjaro were initially created to treat diabetes.

“The strong response to GIMOTI among healthcare providers and patients underscores its growing value as an innovative ...

Despite the recent stock surge, Evoke Pharma’s year-to-date performance tells a different story. The stock is down a notable 57.44%, starkly contrasting with the S&P 500’s impressive 21.77% gain. This ...

The pharmaceutical company said its nasal spray known broadly as GIMOTI offers substantial benefits to patients of diabetic ...

Metoclopramide is used for the symptomatic treatment of post-operative or chemotherapy-induced nausea and vomiting, gastroesophageal reflux disease and gastroparesis. Metoclopramide is generally ...

The real-world retrospective study evaluated the impact of GIMOTI (metoclopramide nasal spray) in patients with diabetic gastroparesis (DGP) who were concurrently using GLP-1 receptor agonists. GLP-1 ...